"21-ICRAD" Nucleic NanoVaccines for Fish

水产养殖是增长最快的食品生产部门，但它受到传染病的严重制约。病毒感染对鱼类健康和福利的影响特别大，涉及重大经济损失，可用的疫苗很少。因此，开发预防鱼类病毒病的新疫苗对可持续水产养殖的发展至关重要。针对鱼类病毒感染的实验DNA疫苗已经开发出来，其中一些提供了高度保护，但它们是注射的，不容易接种到幼鱼身上。重要的是，最近有几种DNA疫苗已经商业化，但价格仍然很高。基因疫苗有很大的希望，但它们才刚刚开始在鱼类身上进行测试。在哺乳动物中，它们通常会引起强烈的反应和良好的保护。在这种情况下，NucNanoFish项目建议建立一个使用可生物降解的纳米颗粒的核酸平台，通过肌肉内(IM)或口服/浸泡途径有效地提供疫苗，以对抗几个欧洲养殖鱼种的众所周知的病毒疾病。我们通过每个财团合作伙伴的尖端专业知识选择了四种不同的相关宿主-病原体模型。NucNanoFish将设计、生产和测试DNA/mRNA核酸疫苗，无论是否装载在安全设计的脂纳米颗粒(LNP)上。LNP是基于聚乳酸/乙醇酸(PLGA)核心和脂质冠层。我们推测，它们被黏膜有效摄取或在注射部位招募抗原提呈细胞(APC)将有利于保护性免疫-ICRAD NucNanoFish-ID：103/51在每个相关病毒的入口处的反应。为了实现这些目标，NucNanoFish组建了一个由六个合作伙伴组成的联盟，具有高度互补性的专业知识：一个是使用LNP纳米传递抗原和信使核糖核酸，四个鱼类免疫病毒学家/疫苗专家小组，以及一个DNA生产生物技术公司。

Aquaculture is the fastest growing food production sector, but it is significantly constrained by infectious diseases. Impact of viral infectionson fish health and welfare is particularly strong, involving important economic losses, and only few vaccines are available. Therefore, it is ofparamount importance to develop new vaccines to prevent fish viral diseases for the development of a sustainable aquaculture.Experimental DNA vaccines against fish viral infections have been developed, some providing high protection but they are injected andcannot be easily administered to young fish. Importantly, several DNA vaccines have been recently made commercially available but remainexpensive. mRNA vaccines hold much hope, but they are just beginning to be tested in fish. In mammals, they often induce strongresponses and good protection. They appear to be fast to produce and safer than DNA vaccines as they should not integrate into hostgenomes.In this context, the NucNanoFish project proposes to establish a nucleic acid platform using biodegradable nanoparticles for efficientdelivery of vaccines, through intra-muscular (IM) or oral/immersion routes, against to well-known viral diseases of severalEuropean farmed fish species. We have selected four different relevant host-pathogen models through cutting edge expertise of eachconsortium's partner. NucNanoFish will design, produce and test DNA/mRNA nucleic acid vaccines loaded or not onto safe-by-designLipoNanoParticles (LNP). LNP are based on a PLA/PLGA (Poly-Lactic/Glycolic Acid) core surrounded with a lipid corona. We hypothesize thattheir efficient uptake by mucosa or the recruitment of Antigen Presenting Cells (APC) at the site of injection will favour a protective immuneICRAD NucNanoFish - ID: 10 3 of 51response at the portal of entry of each relevant virus. To achieve these goals, NucNanoFish has assembled a consortium of six partners, withhighly complementary expertise: one in nanodelivery of antigen and mRNA using LNP, four groups of fish immunovirologists / vaccinologistsand a biotech company in DNA production.